Literature DB >> 6121577

Antihypertensive effect of diacetolol in essential hypertension.

M Thibonnier, C Flabeau, M Thouvenin, A Roux, B Flouvat, P Pasquier, J Menard.   

Abstract

1 Diacetolol is the N-acetylated metabolite of acebutolol and possesses beta-adrenergic receptor blocking properties. 2 Its antihypertensive action was assessed in accordance with a double-blind randomised cross-over scheme in 17 patients with moderate essential hypertension previously well controlled with acebutolol. 3 Significant reductions in lying mean arterial blood pressure were observed with daily doses of 200 mg (- 9%), 400 mg (- 10%) and 800 mg (- 14%), and were associated with significant decreases in heart rate and plasma renin activity. 4 The diacetolol mean plasma level measured 8 to 10 h after drug ingestion was proportional to the dose (207 +/- 27, 394 +/- 63 and 823 +/- 135 ng/ml for respectively 200, 400 and 800 mg/day).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121577      PMCID: PMC1402058          DOI: 10.1111/j.1365-2125.1982.tb01417.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Adverse drug reactions during treatment of hypertension.

Authors:  G S Kellaway
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  Acebutolol in hypertension: relationships between drug concentration and effects.

Authors:  M A Martin; F C Phillips; G T Tucker; A J Smith
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.

Authors:  H M Perry; E M Tan; S Carmody; A Sakamoto
Journal:  J Lab Clin Med       Date:  1970-07

4.  Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.

Authors:  B Flouvat; A Roux; N P Chau; M Viallet; X Andre-Fouet; R Woehrle; J Gregoire
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

5.  [Sensitive method for the determination of acebutolol and its N-acetyl metabolite in biological media by high performance liquid chromatography and fluorescence detection].

Authors:  A Roux; B Flouvat
Journal:  J Chromatogr       Date:  1978-12-01

6.  Lack of correlation between acetylator status and the production of the acetyl metabolite of acebutolol in man.

Authors:  A Gulaid; I M James; C M Kaye; O R Lewellen; E Roberts; M Sankey; J Smith; R Templeton; R J Thomas
Journal:  Br J Clin Pharmacol       Date:  1978-03       Impact factor: 4.335

7.  Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension.

Authors:  F Alhenc-Gelas; P F Plouin; M B Ducrocq; P Corvol; J Menard
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

8.  Acebutolol metabolite plasma concentration during chronic oral therapy.

Authors:  R A Winkle; P J Meffin; W B Ricks; D C Harrison
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

9.  Controlled trial of acebutolol in hypertension.

Authors:  L Hansson; G Berglund; O Andersson; M Holm
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

10.  Development of antinuclear antibodies during acebutolol therapy.

Authors:  R J Cody; L H Calabrese; J D Clough; R C Tarazi; E L Bravo
Journal:  Clin Pharmacol Ther       Date:  1979-06       Impact factor: 6.875

View more
  1 in total

1.  Comparative beta-adrenoceptor blocking effects of propranolol, bisoprolol, atenolol, acebutolol and diacetolol on the human isolated bronchus.

Authors:  E Naline; B Sarria; O Ertzbischoff; P Ozanne; C Advenier
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.